Article Text

other Versions

PDF
Drug-eluting stents for the treatment of coronary artery disease: NICE technology appraisal guidance
  1. Joanna Richardson
  1. National Institute for Health and Clinical Excellence (NICE), United Kingdom
    1. Andrew Stevens
    1. National Institute for Health and Clinical Excellence (NICE), United Kingdom
      1. David Barnett (dbb1{at}le.ac.uk)
      1. National Institute for Health and Clinical Excellence (NICE), United Kingdom
        1. Carole Longson
        1. National Institute for Health and Clinical Excellence (NICE), United Kingdom

          Abstract

          NICE Guidance on the use of drug-eluting stents (DES) was published in July 2008 . The guidance replaces sections 1.2 1.4 of NICE technology appraisal guidance number 71 which was published in 2003 . This part-review indicates under what circumstances drug-eluting stents are recommended as a cost effective use of NHS resources in England and Wales. 1. Drug-eluting stents are recommended for use in percutaneous coronary intervention for the treatment of coronary artery disease, within their instructions for use, only if: • the target artery to be treated has less than a 3 mm calibre or the lesion is longer than 15 mm, and • the price difference between drug-eluting stents and bare-metal stents is no more than £300.

          Statistics from Altmetric.com

          Request permissions

          If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

          Linked Articles